Canadian Biosimilars Body Calls For Expansion Of Switching
Other Provinces Urged To Emulate British Columbia And Alberta Programs
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.
